Beyond Kratom: 7-Hydroxymitragynine and the New Wave of Designer Opioids-Recording - Beyond Kratom: 7-Hydroxymitragynine and the New Wave of Designer Opioids

Recording - Beyond Kratom: 7-Hydroxymitragynine and the New Wave of Designer Opioids

Video Transcription

Video Summary

Dr. Jason Kirby presents an overview of kratom and especially 7-hydroxymitragynine (7-OH), warning that highly concentrated, commercially sold 7-OH products are functioning like designer opioids. He explains that while kratom leaf has long been used traditionally, 7-OH is far more potent, binds strongly to mu-opioid receptors, and can cause tolerance, dependence, withdrawal, and opioid-like compulsive use.<br /><br />Kirby describes products sold in vape shops and gas stations as tablets, gummies, liquids, and flavored items, often with misleading labeling and no reliable dosing standards or regulatory oversight. He notes that routine drug screens do not detect kratom unless special tests are ordered. Clinical effects can include anxiety, diarrhea, sweating, cravings, insomnia, constipation, liver injury, seizures, serotonin syndrome, and possible respiratory depression, especially with alcohol, benzodiazepines, or other opioids.<br /><br />He shares a patient case showing classic opioid withdrawal after 7-OH use and emphasizes that treatment can include supportive care, but buprenorphine is currently the best-studied option, with methadone also helpful. He urges clinicians to ask nonjudgmentally about kratom, supplements, and vape-shop substances. The talk closes with a public health warning: stronger kratom derivatives may fuel a new opioid crisis unless regulation, testing, and education improve.

Keywords

kratom

7-hydroxymitragynine

designer opioids

mu-opioid receptors

opioid withdrawal

buprenorphine

vape shop products

substance dependence

public health warning